Sales revenue

Recent Articles

RELATED ARTICLES

  1. The Fosun-backed drugmaker’s privatization comes as its stock price has wilted over 60% since its IPO five years ago and it failed to use the listing to raise additional funds.
    Shunned by investors, Henlius hangs up on its Hong Kong listing
    2696.HK
  2. Akeso marks profit milestone with swift rights issue
    9926.HK
  3. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  4. Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
    1672.HK
  5. Hutchmed scores U.S. success with cancer drug, but profits still dip
    HCM.US 0013.HK
  6. BeiGene’s aggressive expansion brings revenue jolt
    BGNE.US 6160.HK 688235.SHG
  7. Everest reaches new heights on growing drug sales
    1952.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva